At the presentation of the Takeda Pharmaceutical Company Limited financial results for the fiscal year 2020 (period ended 31 March 2021), President and CEO Christophe Weber says:
“Takeda remained resilient as we operated in new ways through the COVID-19 pandemic. We maintained business continuity, ensured patient access to our medicines and safeguarded the health and well-being of our employees. This enabled us to deliver on our full-year management guidance, with underlying revenue growth driven by our 14 global brands.”
During 2020 the growth in the HAE portfolio was driven by excellent performance from Takhzyro, which continues to expand the HAE prophylaxis market, as well as launching into additional geographies.
“As we celebrate Takeda’s 240th anniversary in June 2021, I am extremely proud of our progress and confident in our outlook for the future. We will advance on our growth trajectory, maximize value creation for all of our stakeholders, and continue to position the company for long-term success”, says Christophe Weber.
(Source: Takeda)
